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Within the last 10 years, prostate cancer has become the most
common malignancy among men in England and Wales. The age-
standardised incidence rate exceeded that for colorectal cancer by
1993, and overtook the (declining) rate for lung cancer in 1999
(Quinn et al, 2001). By the early 2000s, approximately 29 000 men
were diagnosed each year with prostate cancer, accounting for one
in four of all new cancers in men (excluding nonmelanoma skin
cancer). Prostate cancer is rare under the age of 50 years, but
incidence rises steeply with age, reaching nearly 1000 cases per
100 000 per year (1% annual risk) in men aged 85 years and more.
Each year, there are some 9000 deaths from prostate cancer,
approximately one in eight of all cancer deaths in men (Office for
National Statistics, 2003).
The causes of prostate cancer are not well known. Family history
in first-degree relatives is a risk factor, and incidence is 60% higher
in African Americans and 38% lower in Asian Americans than in
US Whites (Platz and Giovannucci, 2006), but possible risk factors
related to nutrition, environment, lifestyle, sexual history,
occupation and ethnicity have not been conclusively identified.
The natural history of prostate cancer is poorly understood,
ranging from clinically indolent cancers to highly aggressive and
often fatal disease (Breslow et al, 1977). Treatment in the 1990s
included various combinations of surgery, radiotherapy, che-
motherapy and endocrine therapy, but early disease was some-
times managed by ‘watchful waiting’, and other modalities, such as
cryotherapy, ultrasound and laser treatment have also been used
for local disease control (Kirby, 1996a, b).
Age-standardised incidence of prostate cancer rose slowly from
1971 up to the late 1980s, but tripled during the 1990s to more than
90 cases per 100 000 per year. This rapid increase is largely
attributable to the increasingly widespread use of prostate-specific
antigen (PSA) testing, which has led to an increase in the recorded
incidence of localised prostate cancer (Evans and Møller, 2003;
Pashayan et al, 2006a, b).
Prostate cancer is now more common among the affluent. In the
early 1980s, incidence was 35–40 cases per 100 000 per year in all
deprivation groups. In the decade up to the mid-1990s, however,
incidence increased more than two-fold among the most affluent
men, more rapidly than among the most deprived men, and is now
about 40% higher in the most affluent groups (Quinn et al, 2001).
Age-standardised mortality rates remained stable from 1950 to the
1980s before rising gradually, reaching a peak of 31 cases per
100 000 per year in 1993, then declining slightly thereafter.
We analysed the data for over 201 000 men diagnosed with a
first, primary, malignant neoplasm of the prostate in England and
Wales during the 14-year period 1986– 1999 and who were
followed up to the end of 2001, some 86% of the 233 000 men
potentially eligible for inclusion. Approximately 9% (19 800 men)
had a recorded survival of zero, most of them who were registered
solely from a death certificate, but for a further 1.4% (3300) the
vital status was unknown on 5 November 2002, when the data were
extracted for analysis, and 3.2% (7500) of men were excluded
because the prostate cancer was not their first primary cancer.
The vast majority of prostate cancers are adenocarcinoma (Ross
and Schottenfeld, 1996). The proportion so described in England
and Wales rose from just under 60% of all cases in the early 1990s
to approximately 85% by the early 2000s, in parallel with a decline
in the proportion coded as epithelial malignancy without further
specification, from 28 to approximately 10% (data not shown).
This pattern suggests steady improvement in the recording of
pathological data, rather than a shift in the type of malignancy.
SURVIVAL TRENDS
For men diagnosed during 1996–1999, 1-year survival rose to 89%,
from 78% a decade or so earlier. This represents a rapid
deprivation-adjusted increase of some 6% every 5 years since
1986– 1990 (Table 1, Figure 1).
Five-year survival has increased with extraordinary rapidity
from 43% for men diagnosed during 1986–1990 to 68% for men
diagnosed during 1996–1999, an average deprivation-adjusted
increase of almost 16% (95% CI: 14.8– 17.0%) every 5 years.
For men diagnosed during 1991–1995 and followed up to 2001,
10-year survival had risen to 41%, a similarly rapid rate of increase.
Hybrid analysis (Brenner and Rachet, 2004) based on the follow-
up of survivors during 2000–2001 suggests that survival will
continue to improve, but more slowly than over the previous
decade, reaching 90% at 1 year and 70% at 5 years (Table 1).
DEPRIVATION
Despite high overall survival, there is a significant deprivation gap
in survival, which increased significantly during the 1990s
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(Figure 2). Five-year survival for men in the most deprived groups
who were diagnosed during 1996–1999 was some 7% lower than
for men in the most affluent group (deprivation gap –7.2%). This
represents a significant widening of the deprivation gap by an
average of 3.2% every 5 years since 1986–1990 (Table 2).
Hybrid analysis based on the follow-up of men who were
alive during all or part of the period 2000–2001 suggests that
the deprivation gap may not widen any further, with a
deprivation gap of 4 to 7% in relative survival at 1, 5 and 10
years (Table 2).
COMMENT
The recent trends in prostate cancer survival are remarkable. Survival
improved by approximately 5–6% every 5 years between 1971–1975
and 1981–1985, but it did not change at all between the early and late
Table 1 Trends in relative survival (%) by time since diagnosis and calendar period of diagnosis: England and Wales, men (15–99 years) diagnosed during
1986–1999 and followed up to 2001
Calendar period of diagnosisa
Average change (%) Predictionc for patients
1986–1990 1991–1995 1996–1999 every 5 yearsb diagnosed during 2000–2001
Time since
diagnosis
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
1 year Men 78.3 (77.9, 78.7) 82.5 (82.2, 82.8) 88.9 (88.6, 89.2) 6.2** (5.5, 6.8) 89.9 (89.5, 90.3)
5 years Men 42.7 (42.1, 43.3) 55.1 (54.6, 55.6) 68.4 (67.7, 69.0) 15.9** (14.8, 17.0) 69.9 (69.2, 70.6)
10 years Men 28.2 (27.5, 28.8) 41.1 (40.2, 41.9) 16.4** (13.8, 19.0) 54.0 (52.8, 55.2)
CI¼ confidence interval. aSurvival estimated with cohort or complete approach (see Rachet et al, 2008). bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008). cSurvival estimated with hybrid approach (see Rachet et al, 2008). **Po0.01.
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Figure 1 Relative survival (%) up to 10 years after diagnosis by calendar
period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001. Survival estimated with
cohort or complete approach (1986–1990, 1991–1995, 1996–1999) or
hybrid approach (2000–2001) (see Rachet et al, 2008).
40
50
60
70
80
5-
ye
a
r 
re
la
tiv
e
 
su
rv
iv
a
l (%
)
Affluent 2 3 4 Deprived
Deprivation category
2000–2001
1996–1999
1991–1995
1986–1990
Men
Figure 2 Trends in the deprivation gap in 5-year relative survival (%) by
calendar period of diagnosis: England and Wales, adults (15–99 years)
diagnosed during 1986–1999 and followed up to 2001.
Table 2 Trends in the deprivation gap in relative survival (%) by time since diagnosis and calendar period of diagnosis: England and Wales, men
(15–99 years) diagnosed during 1986–1999 and followed up to 2001
Calendar period of diagnosisa
Average change (%) Predictionc for patients
1986–1990 1991–1995 1996–1999 every 5 yearsb diagnosed during 2000–2001
Time since
diagnosis
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Men 3.0** (4.2, 1.8) 4.2** (5.1, 3.3) 4.1** (4.9, 3.3) 0.6 (1.3, 0.2) 4.4** (5.5, 3.3)
5 years Men 1.2 (2.9, 0.4) 6.0** (7.4, 4.6) 7.2** (9.0, 5.5) 3.2** (4.5, 2.0) 7.3** (9.2, 5.3)
10 years Men 0.0 (1.9, 1.8) 4.9** (7.3, 2.5) 4.9** (7.9, 1.8) 6.7** (9.9, 3.6)
CI¼ confidence interval. aSurvival estimated with cohort or complete approach (see Rachet et al, 2008). bMean absolute change (%) in the deprivation gap in survival every
5 years, adjusted for the underlying trend in survival (see Rachet et al, 2008). cSurvival estimated with hybrid approach (see Rachet et al, 2008). **Po0.01.
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1980s (Coleman et al, 1999). The very rapid increase reported here,
represents a sharp reacceleration of survival during the 1990s.
However, the patterns and trends in prostate cancer incidence
and survival are not an artefact. They reflect a rapid and substantial
shift in the biological and clinical spectrum of prostate cancer, as we
now define, diagnose, register and treat it, following the introduction
of sensitive new diagnostic techniques such as the PSA test.
The PSA test enables invasive prostate cancer to be identified
earlier than it might have been diagnosed clinically on the basis of
symptoms, but the test also enables the identification of latent tumours
that may never have caused symptoms during the man’s lifetime
(Horwich et al, 1995). Thus, the chance of a man in England and Wales
being diagnosed with prostate cancer between his sixtieth and eightieth
birthdays rose from 4%, based on the pattern of incidence by age
throughout the 1980s, to just 5% by 1990, but it almost doubled over
the next 10 years to reach 9% by 2000 (Table 3). At a population level,
therefore, prostate cancer as defined in the PSA era since the early
1990s is no longer the same disease as it was in the 1980s.
In the absence of widespread access to a substantially improved
treatment for early prostate cancer in the last 15 years of the 20th
century, it seems most likely that the extremely rapid improvement
in recorded survival for men diagnosed with prostate cancer
during the period 1986– 1999 reflects an increase in the diagnosis,
treatment and registration of men with asymptomatic malignancy
as a result of the increasingly widespread use of PSA tests during
the 1990s (Evans and Møller, 2003).
The concurrent increase in the difference in survival between
affluent and deprived men, taken with the increase in incidence,
similarly more rapid among men in affluent groups, also suggests
that affluent men have had greater access to PSA tests than men in
the more deprived groups.
A minority of cases (8.5%) were excluded from analysis because
the only available information was from a death certificate; hence,
their duration of survival was unknown. These men probably have
had shorter survival than the average for men who were registered
during their lifetime (Berrino et al, 1995). The proportion of such
cases differed very little among deprivation categories or over
time; however, (data not shown), so their exclusion is most
unlikely to have biased the estimates of the widening deprivation
gap in survival.
In Europe, the international range in 5-year survival for men
diagnosed with prostate cancer during 1990–1994 was wider than
for any other cancer, ranging from 39% in Poland to 85% in
Austria (Sant et al, 2003). Survival in the Nordic countries was
high, and rose further during the 12 years up to 1994, with the
exception of Denmark, where survival was lower and barely
increased at all (Coleman et al, 2003). As with the socioeconomic
differences in the incidence and survival trends reported here,
these patterns seem likely to be at least in part attributable to
international differences in the intensity of diagnostic and
screening activity.
The implications for asymptomatic men diagnosed with prostate
cancer following a PSA test are important. The randomised trials
of mass screening for prostate cancer with the PSA test are not
expected to report mortality results until 2010 (de Koning et al,
2002; Hakama et al, 2008).
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